Asparaginase Market Is Projected to Reach at a 420 Million USD by the End of 2025, with a CAGR of 1.1%: QY Research, Inc.
Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.
View full press release